MD-ROBOTIC-RESEARCH
9.12.2021 07:02:04 CET | Business Wire | Press release
Robotic Research, a global leader in autonomous mobility and robotics solutions, today announced a $228 million funding round—the first outside capital the company has raised. This funding will drive further innovation and expansion of Robotic Research’s commercial division, RR.AI , which is focused on delivering comprehensive autonomous driving solutions for commercial truck, bus, drayage and logistics vehicles. Investors in the Series A round include SoftBank Vision Fund 2, Enlightenment Capital, Crescent Cove Advisors, Henry Crown and Company, and Luminar Technologies, Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208006171/en/
“This investment reflects our success in developing autonomous solutions for our U.S. government customers, and will provide the resources needed to meet our growing commercial customer demand and the expansion of our commercial efforts,” said Alberto Lacaze, CEO, Robotic Research. “Our long history and experience has enabled us to develop a proven solution that is not only rugged, safe, and reliable, but also versatile and ideal for operating across a variety of environments, weather conditions, and use cases.”
Robotic Research has successfully deployed autonomous and robotics solutions on roadways around the globe as well as in the industry’s harshest, unstructured environments. The company’s vehicle-agnostic autonomy kit, AutoDrive® , has already been integrated in a variety of vehicles including North America’s first automated heavy-duty transit bus, Class 8 trucks, and yard trucks. AutoDrive® can be used on-road, off-road, or in the yard, making it uniquely suited to provide a 360° autonomous driving solution that spans a variety of complex operational design domains (ODDs).
“We believe that autonomous vehicle technology has the potential to reshape how goods and people are moved around,” said Akshay Naheta, Senior Vice President of SoftBank Group Corp and former Managing Partner at SoftBank Investment Advisers. “Robotic Research has a track record of operating in the commercial sector and has built a differentiated autonomy solution by focusing on tangible, revenue-generating opportunities. We are thrilled to be a financial partner and provide resources needed to accelerate the commercialization of Robotic Research’s solutions.”
This is the first strategic equity investment to date by Luminar, a global leader in automotive-grade lidar hardware and software technology. Robotic Research is working alongside Luminar on strategic opportunities to advance autonomy and has selected Luminar as its long-range lidar provider.
UBS Investment Bank acted as financial advisor and placement agent for Robotic Research. Cravath, Swaine & Moore LLP acted as legal advisor, and Covington & Burling LLP acted as special counsel to Robotic Research.
About RR.AI
RR.AI is the commercial division of Robotic Research––a global technology company that has delivered autonomous mobility and robotics solutions to the defense sector for two decades. RR.AI ’s vehicle-agnostic, full-stack autonomy kit (AutoDrive®) is a proven autonomous driving system for both on and off-road environments and is trusted by industry-leading OEM partners. It is uniquely suited to provide an end-to-end, 360° autonomous driving solution for commercial transportation that spans across complex operational design domains (ODDs). To learn more about RR.AI , visit www.rr.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208006171/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom